folic acidWhat was measured
Measured, with no finding
6,833 endpoints
Show what was measuredHide what was measured
Bcl2/Bax and BclxL/Bax ratios in MCT cells after serum deprivation
decreases, p = 0.05
decreased Bcl2/Bax and BclxL/Bax ratios (P < 0.05)
PMID 10720950 · one of two readings recorded this
renal Bcl2/Bax mRNA ratio
decreases, p = 0.05
Renal mRNA levels encoding for c-myc and BclxL were elevated in ARF while the Bcl2/Bax ratio was decreased (Bcl2 decreased and Bax increased; P < 0.05)
PMID 10720950 · one of two readings recorded this
renal mRNA and protein levels of c-myc, Bcl2, Bax and BclxL (Northern blot, Western blot, immunohistochemistry) in murine kidneys after folic acid-induced ARF
decreases, Bcl2/Bax ratio decreased
Not recorded as a finding: this platform holds no node for the endpoint
Renal mRNA levels encoding for c-myc and BclxL were elevated in ARF while the Bcl2/Bax ratio was decreased (Bcl2 decreased and Bax increased; P < 0.05).
PMID 10720950 · one of two readings recorded this
sensitization to TNF-alpha-induced apoptosis in MCT cells
increases, p = 0.05
sensitization to TNF-alpha-induced apoptosis (P < 0.05)
PMID 10720950 · one of two readings recorded this
sensitization to TNF-alpha-induced apoptosis with enforced BclxL overexpression
decreases, p = 0.01
The latter was prevented by enforced overexpression of BclxL (P < 0.01)
PMID 10720950 · one of two readings recorded this
correlation of galectin-3 mRNA with serum reciprocal creatinine
decreases, p = 0.0001, n = 13
a significant negative correlation between galectin-3 mRNA expression and serum reciprocal creatinine was shown at 48 hours after injury (n = 13, r = -0.94, P: < 0.0001)
PMID 10980121 · one of two readings recorded this
renal galectin-3 mRNA expression in folic acid-induced acute renal failure in rats
increases
Not recorded as a finding: this platform holds no node for the endpoint
In folic acid-induced ARF, galectin-3 mRNA was found to be up-regulated at 2 hours after injury and increased levels continued until at least 7 days post-injury.
PMID 10980121 · both readings recorded this
renal galectin-3 mRNA expression
increases, p = 0.01
galectin-3 mRNA began to increase at 2 hours and extended by 6.2-fold at 48 hours (P: < 0.01 versus normal control rats)
PMID 10980121 · one of two readings recorded this
renal galectin-3 mRNA expression
increases
In folic acid-induced ARF, galectin-3 mRNA was found to be up-regulated at 2 hours after injury and increased levels continued until at least 7 days post-injury
PMID 10980121 · one of two readings recorded this
renal galectin-3 mRNA expression
decreases
galectin-3 mRNA began to increase at 2 hours and extended by 6.2-fold at 48 hours (P: < 0.01 versus normal control rats), and then decreased by 28 days after injury
PMID 10980121 · one of two readings recorded this
Ang-1 immunostaining in renal arterial walls and injured cortical tubules
increases
FA-induced nephropathy was associated with the acquisition of Ang-1 immunostaining in renal arterial walls and in a subset of injured cortical tubules
PMID 11729241 · one of two readings recorded this
capillary proliferation (PCNA) near damaged tubules
increases
A subset of these endothelia expressed proliferating cell nuclear antigen, whereas capillary proliferation was absent in control samples
PMID 11729241 · one of two readings recorded this
renal Ang-1 protein level (Western blot)
increases
Renal Ang-1 protein levels were significantly increased after FA administration, compared with time-matched control values, as assessed by Western blotting
PMID 11729241 · one of two readings recorded this
renal angiopoietin-1 protein level by Western blotting after folic acid administration in mice
increases
Not recorded as a finding: this platform holds no node for the endpoint
Renal Ang-1 protein levels were significantly increased after FA administration, compared with time-matched control values, as assessed by Western blotting.
PMID 11729241 · one of two readings recorded this
renal angiopoietin-1 protein level, Western blotting, in folic acid-induced nephrotoxicity in mice
increases
Not recorded as a finding: this platform holds no node for the endpoint
Renal Ang-1 protein levels were significantly increased after FA administration, compared with time-matched control values, as assessed by Western blotting.
PMID 11729241 · one of two readings recorded this
tubular damage
increases
Tubular damage was detected 1 d after FA administration
PMID 11729241 · one of two readings recorded this
tubular regeneration with patchy atrophy and interstitial fibrosis
unclear
in the next 14 d, most tubules regenerated but patchy atrophy, with interstitial fibrosis, was also observed
PMID 11729241 · one of two readings recorded this
Birth length
no effect
Folic acid-iron and multiple micronutrients increased head and chest circumference of babies, but not length
PMID 12637400 · one of two readings recorded this
birth size (birth weight, length, head and chest circumference) after maternal folic acid alone versus vitamin A alone control
no effect, no effect on birth size
Not recorded as a finding: a node exists but the paper states a different instrument or population
Supplementation with maternal folic acid alone had no effect on birth size.
PMID 12637400 · one of two readings recorded this
birth size (weight, length, head and chest circumference) after maternal folic acid alone vs vitamin A alone control
no effect
Not recorded as a finding: a node exists but the paper states a different instrument or population
Supplementation with maternal folic acid alone had no effect on birth size.
PMID 12637400 · one of two readings recorded this
Birth size
no effect
Supplementation with maternal folic acid alone had no effect on birth size
PMID 12637400 · one of two readings recorded this
Birth size
no effect
Folic acid-iron-zinc had no effect on birth size compared with controls
PMID 12637400 · one of two readings recorded this
Head and chest circumference
increases
Folic acid-iron and multiple micronutrients increased head and chest circumference of babies, but not length
PMID 12637400 · one of two readings recorded this
Incidence of preterm births
no effect
None of the supplement combinations reduced the incidence of preterm births
PMID 12637400 · one of two readings recorded this
Low birth weight (<2500 g)
decreases
reduced the percentage of low birthweight babies (<2500 g) from 43% to 34% (16%; relative risk=0.84, 0.72 to 0.99)
PMID 12637400 · one of two readings recorded this
Low birth weight (<2500 g)
decreases
reduced the percentage of low birthweight babies by 14% (0.86, 0.74 to 0.99)
PMID 12637400 · one of two readings recorded this
Mean birth weight
increases
Folic acid-iron increased mean birth weight by 37 g (95% confidence interval -16 g to 90 g)
PMID 12637400 · one of two readings recorded this
Mean birth weight
increases
Multiple micronutrient supplementation increased birth weight by 64 g (12 g to 115 g)
PMID 12637400 · one of two readings recorded this
ischaemic heart disease events
decreases
reduces IHD events by 88% (95% confidence interval 84% to 91%)
PMID 12829553 · one of two readings recorded this
life years free from an IHD event or stroke gained, from age 55
increases
gaining on average about 11 years of life free from an IHD event or stroke
PMID 12829553 · one of two readings recorded this
proportional reduction in ischaemic heart disease events and in stroke, estimated for a single daily pill (Polypill) from published meta-analyses
decreases, IHD events reduced by 88% (95% CI 84% to 91%); stroke by 80% (71% to 87%)
Not recorded as a finding: the intervention held more than the compound
We estimate that the combination (which we call the Polypill) reduces IHD events by 88% (95% confidence interval 84% to 91%) and stroke by 80% (71% to 87%).
PMID 12829553 · one of two readings recorded this
stroke
decreases
stroke by 80% (71% to 87%)
PMID 12829553 · one of two readings recorded this
CpG methylation at the A(vy) locus in offspring
increases
dietary methyl supplementation of a/a dams with extra folic acid, vitamin B(12), choline, and betaine alter the phenotype of their A(vy)/a offspring via increased CpG methylation at the A(vy) locus
PMID 12861015 · one of two readings recorded this
offspring phenotype and CpG methylation at the A(vy) locus in viable yellow agouti mice
increases
Not recorded as a finding: the intervention held more than the compound
Our results show that dietary methyl supplementation of a/a dams with extra folic acid, vitamin B(12), choline, and betaine alter the phenotype of their A(vy)/a offspring via increased CpG methylation at the A(vy) locus
PMID 12861015 · one of two readings recorded this
6[R] 5-MTHF detected after folic acid administration (storage of isomer)
unclear
at 1 week after the administration of a single dosage 6[R,S] 5-MTHF, we detected 6[R] 5-MTHF following the administration of folic acid, indicating storage of this isomer in the body
PMID 14769778 · one of two readings recorded this
Bioavailability (pharmacokinetic parameters)
increases
All pharmacokinetic parameters demonstrate that the bioavailability of 5-MTHF is higher compared to folic acid
PMID 14769778 · one of two readings recorded this
Peak concentration of 6[S] and 6[R] 5-MTHF isomers
increases
The peak concentration of both isomers following the administration of 6[R,S] 5-MTHF is almost seven times higher compared to folic acid, irrespective of the patient's genotype
PMID 14769778 · one of two readings recorded this
NTD recurrence, folic acid groups
no effect, n = 261
There was one NTD recurrence in the 89 infants/fetuses of women in the multivitamin group and no recurrence in the 172 infants/fetuses of women in the folic acid groups
PMID 1489222 · one of two readings recorded this
NTD recurrence, multivitamin group
no effect, n = 261
There was one NTD recurrence in the 89 infants/fetuses of women in the multivitamin group and no recurrence in the 172 infants/fetuses of women in the folic acid groups
PMID 1489222 · one of two readings recorded this
NTD recurrence, non-randomised control group
unclear, n = 103
there were three recurrences among the 103 infants in this group
PMID 1489222 · one of two readings recorded this
recurrence of neural tube defects in infants/fetuses of women with a previously affected pregnancy
no effect, one recurrence in 89 multivitamin infants/fetuses and none in 172 folic acid infants/fetuses, non-significant
Not recorded as a finding: this platform holds no node for the endpoint
There was one NTD recurrence in the 89 infants/fetuses of women in the multivitamin group and no recurrence in the 172 infants/fetuses of women in the folic acid groups, a non-significant difference.
PMID 1489222 · both readings recorded this
Bcl-2 protein expression in gastric mucosa
decreases
In contrast, the expression of Bcl-2 oncogene protein decreased after folic acid therapy
PMID 15786529 · one of two readings recorded this
Epithelial apoptosis rate in gastric mucosa
increases
Both the epithelial apoptosis rate and the tumor suppressor p53 expression in gastric mucosa significantly increased after folic acid treatment
PMID 15786529 · one of two readings recorded this
Folate concentration in gastric mucosa
increases
The mean of folate concentration in gastric mucosa was 9.03+/-3.37 microg/g wet wt in the folic acid treatment group, which was significantly higher than 6.83+/-3.02 microg/g wet wt in the control group
PMID 15786529 · one of two readings recorded this
gastric epithelial apoptosis rate, Bcl-2 and p53 expression by flow cytometry, gastric mucosa folate concentration
increases
Not recorded as a finding: the comparison was against another active treatment
Both the epithelial apoptosis rate and the tumor suppressor p53 expression in gastric mucosa significantly increased after folic acid treatment.
PMID 15786529 · one of two readings recorded this
p53 protein expression in gastric mucosa
increases
Both the epithelial apoptosis rate and the tumor suppressor p53 expression in gastric mucosa significantly increased after folic acid treatment
PMID 15786529 · one of two readings recorded this
Erythrocyte folate concentration
increases, p = 0.001, n = 31
and 57% (95% CI 40-74%; p<0.001 v placebo), respectively, and decreased plasma homocysteine concentration by 12% (95% CI 4-20%; p = 0.01 v placebo)
PMID 15831910 · one of two readings recorded this
genomic DNA methylation in leucocytes and colonic mucosa; also serum and erythrocyte folate and plasma homocysteine
increases, leucocyte DNA methylation +31% (95% CI 16-47%); colonic mucosa +25% (95% CI 11-39%), p = 0.05
Not recorded as a finding: this platform holds no node for the endpoint
Folic acid supplementation resulted in increases in DNA methylation of 31% (95% CI 16-47%; p = 0.05 v placebo) in leucocytes and 25% (95% CI 11-39%; p = 0.09 v placebo) in colonic mucosa.
PMID 15831910 · one of two readings recorded this
genomic DNA methylation in leucocytes and colonic mucosa; serum and erythrocyte folate; plasma homocysteine
increases, leucocyte DNA methylation +31% (95% CI 16-47%), colonic mucosa +25% (95% CI 11-39%)
Not recorded as a finding: this platform holds no node for the endpoint
Folic acid supplementation resulted in increases in DNA methylation of 31% (95% CI 16-47%; p = 0.05 v placebo) in leucocytes and 25% (95% CI 11-39%; p = 0.09 v placebo) in colonic mucosa.
PMID 15831910 · one of two readings recorded this
Genomic DNA methylation
increases, p = 0.09, n = 31
25% (95% CI 11-39%; p = 0.09 v placebo) in colonic mucosa
PMID 15831910 · one of two readings recorded this
Genomic DNA methylation
increases, p = 0.05, n = 31
increases in DNA methylation of 31% (95% CI 16-47%; p = 0.05 v placebo) in leucocytes
PMID 15831910 · one of two readings recorded this
Plasma homocysteine concentration
decreases, p = 0.01, n = 31
decreased plasma homocysteine concentration by 12% (95% CI 4-20%; p = 0.01 v placebo)
PMID 15831910 · one of two readings recorded this
Serum folate concentration
increases, p = 0.001, n = 31
Folic acid supplementation increased serum and erythrocyte folate concentrations by 81% (95% confidence interval (CI) 57-104%; p<0.001 v placebo)
PMID 15831910 · one of two readings recorded this
Mean arterial pressure
decreases, p = 0.03, n = 14
Folate was associated with a reduction in mean arterial pressure (100 +/- 12 mm Hg vs. 96 +/- 11 mm Hg, placebo vs. folate, p < 0.03)
PMID 15893170 · one of two readings recorded this
Dilator reserve (myocardial flow reserve)
increases, p = 0.05, n = 14
folate increased dilator reserve by 83% in abnormal segments (0.77 +/- 0.59 vs. ml/min/g 1.41 +/- 1.08 ml/min/g, placebo vs. folate, p < 0.05)
PMID 15893170 · one of two readings recorded this
Dilator reserve (myocardial flow reserve)
no effect, n = 14
whereas dilator reserve in normal segments remained unchanged (2.00 +/- 0.61 ml/min/g vs. 2.12 +/- 0.69 ml/min/g, placebo vs. folate, p = NS)
PMID 15893170 · one of two readings recorded this
MBF dose response to adenosine
increases, p = 0.001, n = 14
folic acid significantly increased the MBF dose response to adenosine (p < 0.001 using analysis of variance) in abnormal zones
PMID 15893170 · one of two readings recorded this
MBF dose response to adenosine
no effect, n = 14
whereas MBF in normal zones did not change
PMID 15893170 · one of two readings recorded this
myocardial blood flow and dilator reserve by positron emission tomography
increases, peak MBF +49% in abnormal segments, 1.45 vs 2.16 ml/min/g
Not recorded as a finding: no outcome node for myocardial blood flow or myocardial flow reserve by PET
In abnormal segments, folic acid increased peak MBF by 49% (1.45 +/- 0.59 ml/min/g vs. 2.16 +/- 1.01 ml/min/g, p < 0.02).
PMID 15893170 · one of two readings recorded this
peak myocardial blood flow after adenosine, positron emission tomography, abnormal myocardial zones only
increases, peak MBF 1.45 vs 2.16 ml/min/g, +49%
Not recorded as a finding: no outcome node for PET myocardial blood flow or myocardial flow reserve; result is for abnormal-zone subgroup
In abnormal segments, folic acid increased peak MBF by 49% (1.45 +/- 0.59 ml/min/g vs. 2.16 +/- 1.01 ml/min/g, p < 0.02).
PMID 15893170 · one of two readings recorded this
Peak myocardial blood flow
increases, p = 0.02, n = 14
In abnormal segments, folic acid increased peak MBF by 49% (1.45 +/- 0.59 ml/min/g vs. 2.16 +/- 1.01 ml/min/g, p < 0.02)
PMID 15893170 · one of two readings recorded this
between-study heterogeneity of TT versus CC odds ratios
unclear, p = 0.001
There was strong evidence of heterogeneity (P < 0.001, I2 = 38.4%)
PMID 16216822 · one of two readings recorded this
coronary heart disease (myocardial infarction or coronary artery occlusion), TT versus CC genotype
increases
An overall random effects odds ratio of 1.14 (95% confidence intervals 1.05 to 1.24) was found for TT versus CC genotype
PMID 16216822 · one of two readings recorded this
all-cause mortality
no effect
relative risks (95% CIs) of 1·03 (0·78−1·37) and 1·00 (0·74−1·34) without and with zinc, respectively
PMID 16413878 · one of two readings recorded this
all-cause mortality
no effect
relative risks (95% CIs) of 1·03 (0·78−1·37) and 1·00 (0·74−1·34) without and with zinc, respectively
PMID 16413878 · one of two readings recorded this
all-cause mortality in children aged 1-36 months, intention to treat
no effect, RR 1.03 (0.78-1.37) iron and folic acid; 1.00 (0.74-1.34) with zinc
Not recorded as a finding: the intervention held more than the compound
There was no difference in all-cause mortality by treatment group, with relative risks (95% CIs) of 1·03 (0·78−1·37) and 1·00 (0·74−1·34) without and with zinc, respectively (table 3).
PMID 16413878 · one of two readings recorded this
all-cause mortality in children aged 1-36 months
no effect, RR 1.03 (0.78-1.37) without zinc and 1.00 (0.74-1.34) with zinc
Not recorded as a finding: the intervention held more than the compound
There was no difference in all-cause mortality by treatment group, with relative risks (95% CIs) of 1·03 (0·78−1·37) and 1·00 (0·74−1·34) without and with zinc, respectively (table 3).
PMID 16413878 · one of two readings recorded this
all-cause mortality, interaction with age
no effect, p = 0.86
test for interaction: iron and folic acid vs placebo p=0·86; iron and folic acid with zinc vs placebo p=0·85
PMID 16413878 · one of two readings recorded this
all-cause mortality, interaction with age
no effect, p = 0.85
test for interaction: iron and folic acid vs placebo p=0·86; iron and folic acid with zinc vs placebo p=0·85
PMID 16413878 · one of two readings recorded this
haemoglobin and serum ferritin concentrations
increases
concentrations of both haemoglobin and serum ferritin were significantly higher in the groups taking iron and folic acid than in the placebo group
PMID 16413878 · one of two readings recorded this
incidence of acute lower respiratory illness
no effect
There were no significant differences in the incidence of diarrhoea, persistent diarrhoea, dysentery, or acute lower respiratory illness between the iron and folic acid and placebo groups
PMID 16413878 · one of two readings recorded this
incidence of diarrhoea
no effect
There were no significant differences in the incidence of diarrhoea, persistent diarrhoea, dysentery, or acute lower respiratory illness between the iron and folic acid and placebo groups
PMID 16413878 · one of two readings recorded this
incidence of dysentery
no effect
There were no significant differences in the incidence of diarrhoea, persistent diarrhoea, dysentery, or acute lower respiratory illness between the iron and folic acid and placebo groups
PMID 16413878 · one of two readings recorded this
incidence of persistent diarrhoea
no effect
There were no significant differences in the incidence of diarrhoea, persistent diarrhoea, dysentery, or acute lower respiratory illness between the iron and folic acid and placebo groups
PMID 16413878 · one of two readings recorded this
mortality from other infections
increases
Although the CIs for the point estimate of the relative risk of 3·58 (1·05−13·52) were above 1·00
PMID 16413878 · one of two readings recorded this
overall anaemia rate
decreases
45% (37·7−53·4) and 48% (37·5, 56·2) in the groups taking iron and folic acid without and with zinc
PMID 16413878 · one of two readings recorded this
overall anaemia rate
decreases
45% (37·7−53·4) and 48% (37·5, 56·2) in the groups taking iron and folic acid without and with zinc
PMID 16413878 · one of two readings recorded this
overall anaemia rate
Overall rates of anaemia were 62% (48·2−69·7) in the placebo group
PMID 16413878 · one of two readings recorded this
prevalence of iron-deficiency anaemia, relative reduction vs placebo
decreases
The prevalence of iron-deficiency anaemia was 84% (65−92) lower in the group taking iron and folic acid
PMID 16413878 · one of two readings recorded this
prevalence of iron-deficiency anaemia, relative reduction vs placebo
decreases
53% (18−73) lower in the group taking iron and folic acid with zinc than in the placebo group
PMID 16413878 · one of two readings recorded this
severe anaemia prevalence
decreases
only 1% (0·1−4·6) of those in the iron and folic acid group
PMID 16413878 · one of two readings recorded this
severe anaemia prevalence
decreases
3% (1·1−5·8) of those taking iron and folic acid with zinc were severely anaemic
PMID 16413878 · one of two readings recorded this
severe anaemia prevalence
6% (95% CI 2·6−10·7) of children in the placebo group had severe anaemia
PMID 16413878 · one of two readings recorded this
proportion of total urinary arsenic excreted as DMA
increases, p = 0.0001
The increase in the proportion of total urinary arsenic excreted as DMA in the folic acid group (72% before and 79% after supplementation) was significantly (P < 0.0001) greater than that in the placebo group
PMID 17093162 · one of two readings recorded this
proportion of total urinary arsenic excreted as InAs
decreases, p = 0.001
as InAs (15% and 11%, respectively; P < 0.001)
PMID 17093162 · one of two readings recorded this
proportion of total urinary arsenic excreted as MMA
decreases, p = 0.0001
excreted as MMA (13% and 10%, respectively; P < 0.0001)
PMID 17093162 · one of two readings recorded this
blood DMAs
no effect
There was no change in DMAs in blood
PMID 17921403 · one of two readings recorded this
blood MMAs reduction
decreases, p = 0.0001
MMAs in blood was reduced by a mean +/- SE of 22.24 +/- 2.86% in the folic acid supplementation group and by 1.24 +/- 3.59% in the placebe group (P < 0.0001)
PMID 17921403 · one of two readings recorded this
total blood arsenic and blood MMAs, DMAs, InAs concentrations; urinary DMAs
decreases, total blood arsenic reduced 13.62% vs 2.49% on placebo, p = 0.0199
Not recorded as a finding: this platform holds no node for the endpoint
Total blood arsenic was reduced by 13.62% in the folic acid supplementation group and by 2.49% in the placebo group (P = 0.0199).
PMID 17921403 · one of two readings recorded this
total blood arsenic reduction
decreases, p = 0.0199
Total blood arsenic was reduced by 13.62% in the folic acid supplementation group and by 2.49% in the placebo group (P = 0.0199)
PMID 17921403 · one of two readings recorded this
urinary DMAs
increases, p = 0.0099
DMAs is rapidly excreted in urine as evidenced by an increase in urinary DMAs (P = 0.0099)
PMID 17921403 · one of two readings recorded this
correlation of synthetic folate intake with plasma folate
increases, p = 0.0001, n = 55
Plasma folate | 53 | 0.47 | < 0.001 | 55 | 0.49 | < 0.0001
PMID 17961229 · one of two readings recorded this
correlation of synthetic folate intake with plasma folate
increases, p = 0.001, n = 53
Plasma folate | 53 | 0.47 | < 0.001 | 55 | 0.49 | < 0.0001
PMID 17961229 · one of two readings recorded this
correlation of synthetic folate intake with RBC folate
increases, p = 0.01, n = 55
RBC folate | 53 | 0.31 | < 0.05 | 55 | 0.36 | < 0.01
PMID 17961229 · one of two readings recorded this
correlation of synthetic folate intake with RBC folate
increases, p = 0.05, n = 53
RBC folate | 53 | 0.31 | < 0.05 | 55 | 0.36 | < 0.01
PMID 17961229 · one of two readings recorded this
correlation of total folate intake with plasma folate
increases, p = 0.001, n = 55
Plasma folate | 53 | 0.47 | < 0.001 | 55 | 0.46 | < 0.001
PMID 17961229 · one of two readings recorded this
correlation of total folate intake with plasma folate
increases, p = 0.001, n = 53
Plasma folate | 53 | 0.47 | < 0.001 | 55 | 0.46 | < 0.001
PMID 17961229 · one of two readings recorded this
correlation of total folate intake with RBC folate
increases, p = 0.01, n = 55
RBC folate | 53 | 0.32 | < 0.05 | 55 | 0.36 | <0.01
PMID 17961229 · one of two readings recorded this
correlation of total folate intake with RBC folate
increases, p = 0.05, n = 53
RBC folate | 53 | 0.32 | < 0.05 | 55 | 0.36 | <0.01
PMID 17961229 · one of two readings recorded this
dietary folate intake
Dietary folate, μg/d | 225 (193, 322) | 253 (208, 320) | 271 (214, 331) | 268 (217, 326)
PMID 17961229 · one of two readings recorded this
dietary folate intake
Dietary folate, μg/d | 225 (193, 322) | 253 (208, 320) | 271 (214, 331) | 268 (217, 326)
PMID 17961229 · one of two readings recorded this
percentage correctly classified into folate intake quartile by plasma folate
increases, p = 0.0001, n = 55
Plasma folate | 55 | 47 | 33 | 20 | <0.0001
PMID 17961229 · one of two readings recorded this
percentage correctly classified into folate intake quartile by plasma folate
no effect, p = 0.1427, n = 53
Plasma folate | 53 | 28 | 44 | 28 | 0.1427
PMID 17961229 · one of two readings recorded this
percentage correctly classified into folate intake quartile by plasma folate
unclear, p = 0.0001, n = 18
Plasma folate | 18 | 6 | 50 | 44 | <0.0001
PMID 17961229 · one of two readings recorded this
percentage correctly classified into folate intake quartile by plasma folate
no effect, p = 0.2707, n = 17
Plasma folate | 17 | 18 | 41 | 41 | 0.2707
PMID 17961229 · one of two readings recorded this
percentage correctly classified into folate intake quartile by RBC folate
increases, p = 0.05, n = 55
RBC folate | 55 | 33 | 43 | 24 | < 0.05
PMID 17961229 · one of two readings recorded this
percentage correctly classified into folate intake quartile by RBC folate
increases, p = 0.001, n = 53
RBC folate | 53 | 40 | 40 | 20 | < 0.001
PMID 17961229 · one of two readings recorded this
percentage correctly classified into folate intake quartile by RBC folate
no effect, p = 0.7866, n = 18
RBC folate | 18 | 22 | 39 | 39 | 0.7866
PMID 17961229 · one of two readings recorded this
percentage correctly classified into folate intake quartile by RBC folate
no effect, p = 0.0588, n = 17
RBC folate | 17 | 35 | 30 | 35 | 0.0588
PMID 17961229 · one of two readings recorded this
plasma folate
Plasma folate (nmol/L) | 59 (41, 85) | 46 (29, 63) | 110 (74, 143) | 93 (71, 120)
PMID 17961229 · one of two readings recorded this
plasma folate
Plasma folate (nmol/L) | 59 (41, 85) | 46 (29, 63) | 110 (74, 143) | 93 (71, 120)
PMID 17961229 · one of two readings recorded this
plasma homocysteine
Plasma homocysteine (μmol/L) | 8.8 (8.1, 9.6) | 8.7 (8.0, 9.4) | 9.2 (8.6, 9.8) | 8.9 (8.2, 9.6)
PMID 17961229 · one of two readings recorded this
plasma homocysteine
Plasma homocysteine (μmol/L) | 8.8 (8.1, 9.6) | 8.7 (8.0, 9.4) | 9.2 (8.6, 9.8) | 8.9 (8.2, 9.6)
PMID 17961229 · one of two readings recorded this
prenatal folic acid from supplements
The average amount of folic acid provided by the supplements prenatally was 923 ± 239 μg/d
PMID 17961229 · one of two readings recorded this
proportion with RBC folate above 906 nmol/L
% > 906 nmol/L2 | 100 | 89 | 100 | 100
PMID 17961229 · one of two readings recorded this
proportion with RBC folate above 906 nmol/L
% > 906 nmol/L2 | 100 | 89 | 100 | 100
PMID 17961229 · one of two readings recorded this
RBC folate
RBC folate (nmol/L) | 2190 (1875, 2626) | 1374 (1025, 1692) | 3024 (2313, 3992) | 2090 (1641, 2527)
PMID 17961229 · one of two readings recorded this
RBC folate
RBC folate (nmol/L) | 2190 (1875, 2626) | 1374 (1025, 1692) | 3024 (2313, 3992) | 2090 (1641, 2527)
PMID 17961229 · one of two readings recorded this
synthetic folate intake
Synthetic folate, μg/d3 | 147 (75, 174) | 118 (87, 151) | 472 (408, 511) | 450 (410, 479)
PMID 17961229 · one of two readings recorded this
synthetic folate intake
Synthetic folate, μg/d3 | 147 (75, 174) | 118 (87, 151) | 472 (408, 511) | 450 (410, 479)
PMID 17961229 · one of two readings recorded this
total folate intake
Total folate, μg DFE/d | 481 (400, 561) | 467 (379, 543) | 1072 (983, 1163) | 1040 (953, 1135)
PMID 17961229 · one of two readings recorded this
total folate intake
Total folate, μg DFE/d | 481 (400, 561) | 467 (379, 543) | 1072 (983, 1163) | 1040 (953, 1135)
PMID 17961229 · one of two readings recorded this
composite of myocardial infarction, stroke, coronary revascularization, or CVD mortality
no effect, RR 1.03, 95% CI 0.90-1.19, p = 0.65
Not recorded as a finding: the intervention held more than the compound
Patients receiving active vitamin treatment had similar risk for the composite CVD primary end point (226.9/10,000 person-years vs 219.2/10,000 person-years for the active vs placebo group; relative risk [RR], 1.03; 95% confidence interval [CI], 0.90-1.19; P = .65), as well as for the secondary outcomes including myocardial infarction (34.5/10,000 person-years vs 39.5/10,000 person-years; RR, 0.87; 95% CI, 0.63-1.22; P = .42), stroke (41.9/10,000 person-years vs 36.8/10,000 person-years; RR, 1.14; 95% CI, 0.82-1.57; P = .44), and CVD mortality (50.3/10,000 person-years vs 49.6/10,000 person-years; RR, 1.01; 95% CI, 0.76-1.35; P = .93).
PMID 18460663 · one of two readings recorded this
composite of myocardial infarction, stroke, coronary revascularization, or CVD mortality
no effect, p = 0.65
(226.9/10,000 person-years vs 219.2/10,000 person-years for the active vs placebo group; relative risk [RR], 1.03; 95% confidence interval [CI], 0.90-1.19; P = .65)
PMID 18460663 · one of two readings recorded this
confirmed CVD events (count)
no effect, n = 796
a total of 796 women experienced a confirmed CVD event (406 in the active group and 390 in the placebo group)
PMID 18460663 · one of two readings recorded this
CVD mortality
no effect, p = 0.93
CVD mortality (50.3/10,000 person-years vs 49.6/10,000 person-years; RR, 1.01; 95% CI, 0.76-1.35; P = .93)
PMID 18460663 · one of two readings recorded this
myocardial infarction
no effect, p = 0.42
myocardial infarction (34.5/10,000 person-years vs 39.5/10,000 person-years; RR, 0.87; 95% CI, 0.63-1.22; P = .42)
PMID 18460663 · one of two readings recorded this
plasma homocysteine, difference vs placebo
decreases
for a difference of 2.27 micromol/L (95% CI, 1.54-2.96 micromol/L)
PMID 18460663 · one of two readings recorded this
plasma homocysteine, geometric mean relative decrease
decreases, p = 0.001, n = 300
geometric mean plasma homocysteine level was decreased by 18.5% (95% CI, 12.5%-24.1%; P < .001) in the active group (n = 150) over that observed in the placebo group (n = 150)
PMID 18460663 · one of two readings recorded this
stroke
no effect, p = 0.44
stroke (41.9/10,000 person-years vs 36.8/10,000 person-years; RR, 1.14; 95% CI, 0.82-1.57; P = .44)
PMID 18460663 · one of two readings recorded this
peritubular capillary stability
increases
delivery of angiopoietin-1 by adenoviral vectors stabilized peritubular capillaries in folic acid nephropathy
PMID 18480750 · one of two readings recorded this
profibrotic and inflammatory effects
increases
delivery of angiopoietin-1 by adenoviral vectors stabilized peritubular capillaries in folic acid nephropathy but this was accompanied by profibrotic and inflammatory effects
PMID 18480750 · one of two readings recorded this
adenoma recurrence
decreases
Patients below 70 years of age and those with left-sided colonic adenomas or advanced adenomas responded better to folic acid supplementation
PMID 18680228 · one of two readings recorded this
adenoma recurrence
decreases
Patients below 70 years of age and those with left-sided colonic adenomas or advanced adenomas responded better to folic acid supplementation
PMID 18680228 · one of two readings recorded this
adenoma recurrence
decreases
Patients below 70 years of age and those with left-sided colonic adenomas or advanced adenomas responded better to folic acid supplementation
PMID 18680228 · one of two readings recorded this
mean number of recurrent adenomas
decreases, n = 94
The mean number of recurrent polyps at 3-year was 0.36 (SD, 0.69) for folic acid treated patients compared to 0.82 (SD, 1.17) for placebo treated subjects
PMID 18680228 · one of two readings recorded this
advanced lesion risk
no effect
showed a borderline non-significant inverse association with risk of all adenomas (RR for Q4 vs. Q1=0.83; 95% CI=0.64-1.08, Table 3), but not with advanced lesions (RR for Q4 vs. Q1=0.78; 95% CI=0.39-1.57, Table 3)
PMID 18708408 · one of two readings recorded this
advanced lesion risk
no effect
did not show any association with risk of any adenoma (RR for Q4 vs. Q1=1.05; 95% CI=0.78-1.41) or advanced lesions (RR for Q4 vs. Q1=0.99; 95% CI=0.46-2.12, Table 3)
PMID 18708408 · one of two readings recorded this
advanced lesion risk
no effect
we observed no association with any adenoma (RR for Q4 vs. Q1=1.02; 95%CI=0.85-1.23) or advanced lesions (RR for Q4 vs. Q1=1.07; 95% CI= 0.66-1.73)
PMID 18708408 · one of two readings recorded this
advanced lesion risk
no effect
For advanced lesions, the PL RR for Q4 vs. Q1 was 0.65 (95% CI=0.32-1.32 in a fully adjusted model)
PMID 18708408 · one of two readings recorded this
advanced lesion risk
no effect
there was no association between PLP levels and risk of advanced lesions (RR for Q4 vs. Q1=0.89, 95% CI=0.46-1.73)
PMID 18708408 · one of two readings recorded this
advanced lesion risk
no effect
no significant association between baseline plasma B12 and risk of any adenoma (RR for Q4 vs. Q1=0.91, 95% CI=0.73-1.15) or advanced lesions (RR for Q4 vs. Q1=0.94, 95% CI=0.52-1.69, Table 2)
PMID 18708408 · one of two readings recorded this
advanced lesion risk
decreases, p = 0.12
although there was a statistically significant inverse association for advanced lesions (RR for Q4 vs. Q1=0.51, 95% CI=0.26-0.99, p-trend=0.12, Table 2)
PMID 18708408 · one of two readings recorded this
alcohol consumption, subjects with new adenomas vs without
increases, p = 0.006
but were more likely to have lower baseline plasma folate levels (p=0.025) and consume more alcohol (p=0.006)
PMID 18708408 · one of two readings recorded this
any adenoma recurrence risk
increases
We observed a significantly increased risk for any adenoma recurrence among individuals with the CBS-1080 T/T genotype compared to those with at least one C allele (RR=1.29, 95% CI=1.06-1.56)
PMID 18708408 · one of two readings recorded this
any adenoma risk with higher plasma vitamin B2
no effect
while those who were heterozygotes or homozygotes for the common 677C allele showed a reduced risk (adjusted RR=0.87; 95% CI=0.73-1.03, p-interaction=0.07)
PMID 18708408 · one of two readings recorded this
any adenoma risk with higher plasma vitamin B2
no effect
Among subjects who were homozygotes for the (variant) T allele there was a non-significantly increased risk of adenomas associated with higher plasma vitamin B2 (adjusted RR=1.40; 95% CI=0.85-2.30)
PMID 18708408 · one of two readings recorded this
any adenoma risk
no effect
The relative risk for MTR-2756 A/G or G/G vs. A/A was 0.99 (95% CI=0.85-1.15), for MTRR-66 G/G vs. A/A or A/G it was 0.97 (95% CI=0.83-1.14) and for CBS-699 T/T vs. C/C or C/T it was 0.80 (95% CI=0.62-1.03)
PMID 18708408 · one of two readings recorded this
any adenoma risk
no effect
showed a borderline non-significant inverse association with risk of all adenomas (RR for Q4 vs. Q1=0.83; 95% CI=0.64-1.08, Table 3), but not with advanced lesions (RR for Q4 vs. Q1=0.78; 95% CI=0.39-1.57, Table 3)
PMID 18708408 · one of two readings recorded this
any adenoma risk
no effect
did not show any association with risk of any adenoma (RR for Q4 vs. Q1=1.05; 95% CI=0.78-1.41) or advanced lesions (RR for Q4 vs. Q1=0.99; 95% CI=0.46-2.12, Table 3)
PMID 18708408 · one of two readings recorded this
any adenoma risk
no effect
The relative risk for MTR-2756 A/G or G/G vs. A/A was 0.99 (95% CI=0.85-1.15), for MTRR-66 G/G vs. A/A or A/G it was 0.97 (95% CI=0.83-1.14) and for CBS-699 T/T vs. C/C or C/T it was 0.80 (95% CI=0.62-1.03)
PMID 18708408 · one of two readings recorded this
any adenoma risk
no effect
The relative risk for MTR-2756 A/G or G/G vs. A/A was 0.99 (95% CI=0.85-1.15), for MTRR-66 G/G vs. A/A or A/G it was 0.97 (95% CI=0.83-1.14) and for CBS-699 T/T vs. C/C or C/T it was 0.80 (95% CI=0.62-1.03)
PMID 18708408 · one of two readings recorded this
any adenoma risk
no effect
we observed no association with any adenoma (RR for Q4 vs. Q1=1.02; 95%CI=0.85-1.23) or advanced lesions (RR for Q4 vs. Q1=1.07; 95% CI= 0.66-1.73)
PMID 18708408 · one of two readings recorded this
any adenoma risk
decreases
Baseline PL levels were also inversely associated with all adenoma risk (RR for Q4 vs. Q1=0.78; 95% CI=0.62-0.99)
PMID 18708408 · one of two readings recorded this
any adenoma risk
no effect
an association that was attenuated after further adjustment for plasma B2, B12 and folate (RR for Q4 vs. Q1=0.86; 95% CI=0.66-1.12)
PMID 18708408 · one of two readings recorded this
any adenoma risk
no effect, p = 0.08
Baseline PLP concentration was borderline inversely associated with risk of any adenoma (RR for Q4 vs. Q1=0.78, 95% CI=0.61-1.00, p-trend=0.08, Table 2)
PMID 18708408 · one of two readings recorded this
any adenoma risk
no effect
no significant association between baseline plasma B12 and risk of any adenoma (RR for Q4 vs. Q1=0.91, 95% CI=0.73-1.15) or advanced lesions (RR for Q4 vs. Q1=0.94, 95% CI=0.52-1.69, Table 2)
PMID 18708408 · one of two readings recorded this
any adenoma risk
no effect
Baseline plasma vitamin B2 was not significantly associated with adenoma risk (adjusted RR for Q4 vs. Q1=0.95, 95% CI=0.75-1.20)
PMID 18708408 · one of two readings recorded this
baseline plasma folate, subjects with new adenomas vs without
decreases, p = 0.025
but were more likely to have lower baseline plasma folate levels (p=0.025) and consume more alcohol (p=0.006)
PMID 18708408 · one of two readings recorded this
correlation of dietary B2 intake with plasma B2
increases, p = 0.001
Baseline dietary vitamin B2 was modestly correlated with plasma levels (rho=0.1; p<0.001)
PMID 18708408 · one of two readings recorded this
correlation of dietary B6 intake with plasma PL
increases, p = 0.001
Baseline dietary vitamin B6 intake was modestly correlated with plasma PLP and PL (rho=0.17 and 0.15, respectively; p<0.001)
PMID 18708408 · one of two readings recorded this
correlation of dietary B6 intake with plasma PLP
increases, p = 0.001
Baseline dietary vitamin B6 intake was modestly correlated with plasma PLP and PL (rho=0.17 and 0.15, respectively; p<0.001)
PMID 18708408 · one of two readings recorded this
correlation of plasma B12 with plasma folate
increases
Similarly, plasma B12 and folate were modestly correlated (rho=0.34)
PMID 18708408 · one of two readings recorded this
correlation of plasma B2 with plasma B12
increases
Plasma B2 was modestly correlated with PLP (rho=0.44), PL (rho=0.50), B12 (rho=0.30) and folate (rho=0.45)
PMID 18708408 · one of two readings recorded this
correlation of plasma B2 with plasma folate
increases
Plasma B2 was modestly correlated with PLP (rho=0.44), PL (rho=0.50), B12 (rho=0.30) and folate (rho=0.45)
PMID 18708408 · one of two readings recorded this
correlation of plasma B2 with plasma PL
increases
Plasma B2 was modestly correlated with PLP (rho=0.44), PL (rho=0.50), B12 (rho=0.30) and folate (rho=0.45)
PMID 18708408 · one of two readings recorded this
correlation of plasma B2 with plasma PLP
increases
Plasma B2 was modestly correlated with PLP (rho=0.44), PL (rho=0.50), B12 (rho=0.30) and folate (rho=0.45)
PMID 18708408 · one of two readings recorded this
correlation of plasma PL with plasma B12
increases
both were modestly correlated with plasma vitamin B12 (rho=0.38 and 0.34, respectively) and folate (rho=0.48 and 0.53, respectively)
PMID 18708408 · one of two readings recorded this
correlation of plasma PL with plasma folate
increases
both were modestly correlated with plasma vitamin B12 (rho=0.38 and 0.34, respectively) and folate (rho=0.48 and 0.53, respectively)
PMID 18708408 · one of two readings recorded this
correlation of plasma PLP with plasma B12
increases
both were modestly correlated with plasma vitamin B12 (rho=0.38 and 0.34, respectively) and folate (rho=0.48 and 0.53, respectively)
PMID 18708408 · one of two readings recorded this
correlation of plasma PLP with plasma folate
increases
both were modestly correlated with plasma vitamin B12 (rho=0.38 and 0.34, respectively) and folate (rho=0.48 and 0.53, respectively)
PMID 18708408 · one of two readings recorded this
correlation of plasma PLP with plasma PL
increases
Plasma PLP and PL were strongly correlated (rho=0.82)
PMID 18708408 · one of two readings recorded this
subjects with one or more colorectal adenoma at follow-up
n = 1084
Of the 1,084 subjects with endpoint data, 471 (43.5%) were found to have one or more colorectal adenoma at least one year after randomization
PMID 18708408 · one of two readings recorded this
time from randomization to completion of first follow-up interval
The mean (SD) time from randomization to completion of the first follow-up interval was 32.7 (3.6) months
PMID 18708408 · one of two readings recorded this
augmentation index change during HD
decreases, p = 0.013, n = 10
By contrast, intra-HD F administration was associated with significant increases in F (+298 +/- 283 nmol l(-1), P = 0.010) and a significant reduction of AIx (-4.7 +/- 7.2%, P = 0.013), but no effects on salbutamol-mediated AIx changes (+1.5 +/- 4.4%)
PMID 18754845 · one of two readings recorded this
augmentation index change during HD
no effect, n = 10
Pre-HD F administration did not prevent significant reductions in F during HD (end-HD vs. pre-HD, -865 +/- 465 nmol l(-1), P < 0.001), but no significant changes in AIx (+1.4 +/- 5.7%) or salbutamol-mediated AIx modifications (+0.4 +/- 5.5%) were observed
PMID 18754845 · one of two readings recorded this
HD-induced reduction in plasma ADMA
unclear, p = 0.066, n = 10
There was a trend towards greater HD-induced reductions in plasma ADMA concentrations with intra-HD F administration (P = 0.066)
PMID 18754845 · one of two readings recorded this
plasma folic acid change during HD (end-HD vs pre-HD)
increases, p = 0.01, n = 10
By contrast, intra-HD F administration was associated with significant increases in F (+298 +/- 283 nmol l(-1), P = 0.010) and a significant reduction of AIx (-4.7 +/- 7.2%, P = 0.013), but no effects on salbutamol-mediated AIx changes (+1.5 +/- 4.4%)
PMID 18754845 · one of two readings recorded this
plasma folic acid change during HD (end-HD vs pre-HD)
decreases, p = 0.001, n = 10
Pre-HD F administration did not prevent significant reductions in F during HD (end-HD vs. pre-HD, -865 +/- 465 nmol l(-1), P < 0.001), but no significant changes in AIx (+1.4 +/- 5.7%) or salbutamol-mediated AIx modifications (+0.4 +/- 5.5%) were observed
PMID 18754845 · one of two readings recorded this
salbutamol-mediated augmentation index change during HD
no effect, n = 10
By contrast, intra-HD F administration was associated with significant increases in F (+298 +/- 283 nmol l(-1), P = 0.010) and a significant reduction of AIx (-4.7 +/- 7.2%, P = 0.013), but no effects on salbutamol-mediated AIx changes (+1.5 +/- 4.4%)
PMID 18754845 · one of two readings recorded this
salbutamol-mediated augmentation index change during HD
no effect, n = 10
Pre-HD F administration did not prevent significant reductions in F during HD (end-HD vs. pre-HD, -865 +/- 465 nmol l(-1), P < 0.001), but no significant changes in AIx (+1.4 +/- 5.7%) or salbutamol-mediated AIx modifications (+0.4 +/- 5.5%) were observed
PMID 18754845 · one of two readings recorded this
advanced adenoma, folic acid vs placebo
no effect
these risk ratios were 1.30 (95% CI 0.34, 4.96) and 1.40 (95% CI 0.36, 5.38) respectively
PMID 18768511 · one of two readings recorded this
advanced adenoma, folic acid vs placebo
no effect
these risk ratios were 1.30 (95% CI 0.34, 4.96) and 1.40 (95% CI 0.36, 5.38) respectively
PMID 18768511 · one of two readings recorded this
advanced adenoma recurrence, MTHFR 1298CC vs wild type
no effect, p = 0.71
and 1.16 (0.58–2.33) for the 1298CC genotype (p for trend = 0.71)
PMID 18768511 · one of two readings recorded this
advanced adenoma recurrence, MTHFR 677TT vs wild type
no effect, p = 0.28
The RR’s and 95% CI’s for any advanced lesion were 0.75 (0.36–1.55) for the 677TT genotype (p for trend = 0.28)
PMID 18768511 · one of two readings recorded this
any adenoma, folic acid vs placebo
no effect
1.02 (95% CI 0.62, 1.68) for those carrying the MTHFR 1298CC genotype
PMID 18768511 · one of two readings recorded this
any adenoma, folic acid vs placebo
no effect
The folate/placebo risk ratio for all adenomas was 0.93 (0.57, 1.53) among those with the MTHFR 677TT genotype
PMID 18768511 · one of two readings recorded this
any adenoma, MTHFR 1298CC vs wild type
no effect, p = 0.83
For the 1298CC genotype, these RR’s were 1.15 (95% CI= 0.79, 1.66) and 1.14 (95% CI = 0.79, 1.71) for the folate and placebo groups respectively (p = 0.83)
PMID 18768511 · one of two readings recorded this
any adenoma, MTHFR 1298CC vs wild type
no effect
For the 1298CC genotype, these RR’s were 1.15 (95% CI= 0.79, 1.66) and 1.14 (95% CI = 0.79, 1.71) for the folate and placebo groups respectively (p = 0.83)
PMID 18768511 · one of two readings recorded this
any adenoma, MTHFR 677TT vs wild type
decreases
The adjusted risk ratios for any adenoma were 1.07 (95% CI = 0.79–1.45) in males but 0.48 in females (95% CI 0.25, 0.90; p for interaction=0.05)
PMID 18768511 · one of two readings recorded this
any adenoma, MTHFR 677TT vs wild type
no effect, p = 0.05
The adjusted risk ratios for any adenoma were 1.07 (95% CI = 0.79–1.45) in males but 0.48 in females (95% CI 0.25, 0.90; p for interaction=0.05)
PMID 18768511 · one of two readings recorded this
any adenoma, MTHFR 677TT vs wild type
no effect, p = 0.85
For the 677TT genotype, the relative risks for any adenoma were 0.82 (95% CI 0.55, 1.22) and 0.96 (95% CI 0.66, 1.38) among subjects randomized to folate, and placebo respectively (p for interaction =0.85)
PMID 18768511 · one of two readings recorded this
any adenoma, MTHFR 677TT vs wild type
no effect
For the 677TT genotype, the relative risks for any adenoma were 0.82 (95% CI 0.55, 1.22) and 0.96 (95% CI 0.66, 1.38) among subjects randomized to folate, and placebo respectively (p for interaction =0.85)
PMID 18768511 · one of two readings recorded this
any recurrent adenoma, MTHFR 1298CC vs wild type
no effect, p = 0.12
and 1.14 (0.87–1.50) for the MTHFR 1298CC genotype (p for trend = 0.12)
PMID 18768511 · one of two readings recorded this
any recurrent adenoma, MTHFR 677TT vs wild type
no effect, p = 0.42
the adjusted RRs and 95% confidence intervals (CI’s) for any adenoma were 0.89 (0.68–1.16) for the MTHFR 677TT genotype (p for trend over number of variant alleles = 0.42)
PMID 18768511 · one of two readings recorded this
colorectal adenoma recurrence at year-3 surveillance colonoscopy, folic acid versus placebo within MTHFR genotype strata
no effect, folate/placebo risk ratio for all adenomas 0.93 (0.57, 1.53) among MTHFR 677TT carriers and 1.02 (0.62, 1.68) among 1298CC carriers
Not recorded as a finding: every result is a subgroup, with no whole-population estimate
The folate/placebo risk ratio for all adenomas was 0.93 (0.57, 1.53) among those with the MTHFR 677TT genotype and 1.02 (95% CI 0.62, 1.68) for those carrying the MTHFR 1298CC genotype.
PMID 18768511 · one of two readings recorded this
colorectal adenoma recurrence, folic acid 1 mg/day versus placebo, by MTHFR genotype (677TT, 1298CC)
no effect, folate/placebo risk ratio for all adenomas 0.93 (0.57, 1.53) in 677TT carriers and 1.02 (0.62, 1.68) in 1298CC carriers
Not recorded as a finding: every result is a subgroup, with no whole-population estimate
The folate/placebo risk ratio for all adenomas was 0.93 (0.57, 1.53) among those with the MTHFR 677TT genotype and 1.02 (95% CI 0.62, 1.68) for those carrying the MTHFR 1298CC genotype.
PMID 18768511 · one of two readings recorded this
any cancer death
no effect, p = 0.32
There was no difference in any cancer death (24.6/10000 person-years vs 30.1/10000 person-years; HR, 0.82; 95% CI, 0.56–1.21; P=.32)
PMID 18984888 · one of two readings recorded this
any cancer death
no effect
the null results remained for total invasive cancer (148 vs 140 cases; HR, 1.04; 95% CI, 0.83–1.32), breast cancer (59 vs 64 cases; HR, 0.91; 95% CI, 0.64–1.30), and any cancer death (29 vs 36 cases; HR, 0.80; 95% CI, 0.49–1.30)
PMID 18984888 · one of two readings recorded this
any cancer death
no effect
After excluding the first 2 years of follow-up as pre-specified, the HRs were 0.94 (95% CI, 0.73–1.20) for total invasive cancer, 0.73 (95% CI, 0.50–1.06) for breast cancer, and 0.92 (95% CI, 0.53–1.60) for any cancer death
PMID 18984888 · one of two readings recorded this